



November 02, 2021

To,
The Manager,
Listing & Compliance,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Ref: Scrip Code - 506405

Sub: Investor Presentation for Q2FY22.

Dear Sir/Madam,

Pursuant to Regulation 30(6) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we are enclosing herewith Investor Presentation on the Company's Financial Performance of Q2FY22.

The said presentation will also be made available at the website of the Company at www.dmcc.com

You are requested to kindly take the same on your record.

Thanking you,

For The Dharamsi Morarji Chemical Company Limited

Omkar Mhamunkar
Company Secretary & Compliance Officer
ICSI Membership No. ACS 26645

Encl : As Above

CIN NUMBER: L24110MH1919PLC000564

Earnings Presentation

Q2FY22 EARNINGS PRESENTATION
(November 2021)

BSE – DHARAMSI / 506405

Bloomberg – DMCC:IN

The Dharamsi Morarji Chemical Co. Limited

100 + years of expertise in Sulphur Chemistry



THE DHARAMSI MORARJI CHEMICAL CO. LTD.



TOGETHER FOR
SUSTAINABILITY



Responsible Care®
OUR COMMITMENT TO SUSTAINABILITY

DMCC

Safe Harbour

This investor presentation has been prepared by The Dharamsi Morarji Chemicals Company Limited (“DMCC”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements”, including those relating to the general business plans and strategy of DMCC, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to risks with respect to its hair care, its healthcare business and its skin care business. DMCC may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

QUARTERLY UPDATES

MANAGEMENT REMARKS

UPDATES ON CAPEX

CONTACT US

Inside the
document

To view our **corporate film**
Visit: <https://bit.ly/3ePHS7S>
or Scan the QR code.



Financial Statement Summary

CONSOLIDATED P&L STATEMENT

Figures in INR Crores

PARTICULARS	Q2 FY22	Q1 FY22	Q2 FY21	H1 FY22	H1 FY21
Revenue from Operations	72.53	70.65	49.77	143.18	88.93
Total Income	73.39	72.46	55.88	145.85	95.42
Total Operating Expense	65.46	59.67	40.45	125.12	71.87
EBITDA	7.93	12.79	15.43	20.73	23.55
EBITDA Margins %	10.93%	18.10%	31.01%	14.48%	26.48%
Interest Cost	0.73	0.49	0.73	1.22	1.16
Depreciation and Amortisation	1.81	1.79	1.73	3.60	3.36
Profit Before Taxes	5.39	10.51	12.97	15.91	19.03
Profit After Taxes	3.66	7.52	11.68	11.18	17.10*

CLICK HERE to view the financial results - <https://www.bseindia.com/xml-data/corpfiling/AttachLive/48d8fa54-0979-4a2a-b16e-6e6f496b9ecf.pdf>

Y-o-Y

(H1 FY22 vs H1 FY21)

61.00% ▲

H1FY22 Revenue from Operations at INR 143.18 crores as compared to INR 88.93 crores in H1FY21

11.77% ▼

H1FY22 EBITDA at INR 20.73 crores as compared to INR 23.55 crores in H1FY21

16.40% ▼

H1FY22 PBT at INR 15.91 crores as compared to INR 19.03 crores in H1FY21

34.62% ▼

H1FY22 Profit After Tax at INR 11.18 crores as compared to INR 17.10 crores * in H1FY21. *12.16 after adjusting profit from sale of Khemli unit. Actual drop in PAT ~ 8%

Q-o-Q

(Q2 FY22 vs Q2 FY21)

02.66% ▲

Q2FY22 Revenue from Operations at INR 72.53 crores as compared to INR 70.65 crores in Q1FY21

37.99% ▼

Q2FY22 EBITDA at INR 7.93 crores as compared to INR 12.79 crores in Q1FY21

48.72% ▼

Q2FY22 PBT at INR 5.39 crores as compared to INR 10.51 crores in Q1FY21

51.33% ▼

Q2FY22 Profit After Tax at INR 3.66 crores as compared to INR 7.52 crores in Q1FY21. Higher taxation provision on account of normal taxation as compared to MAT

Financial Statement Summary

CONSOLIDATED BALANCE SHEET

Figures in INR Crores

PARTICULARS	H1 FY22	FY21
Shareholder Fund	183.44	173.18
Non Current Liabilities	55.60	21.85
Current Liabilities	95.38	68.67
Total Liabilities	334.49	263.71
Non Current Assets	222.34	148.56
Current Assets	112.15	115.15
Total Assets	334.49	263.71

CWIP

Capital Work in Progress stood at INR 93.08 crores.

LT Borrowings

Long term borrowings increased to INR 52.79 crores in H1FY22 as against INR 19.15 crores in FY21.

ST Borrowings

The higher input costs and volumes led to increased working capital requirement. Short term borrowings increased to INR 14.06 crores as against INR 7.90 crores in FY21

CLICK HERE to view the financial results - <https://www.bseindia.com/xml-data/corpfiling/AttachLive/48d8fa54-0979-4a2a-b16e-6e6f496b9ecf.pdf>

Financial Statement Summary

CONSOLIDATED CASH FLOW STATEMENT

Figures in INR Crores

PARTICULARS	H1 FY22	H1 FY21
Cash Flow from Operating Activities	16.35	14.57
Cash Flow from Investing Activities	-55.13	-13.43
Cash Flow from Financing Activities	36.48	-5.44
Net Increase / Decrease In Cash And Cash Equivalents	-2.31	-4.30
Cash and Cash Equivalents at Beginning of the Period	3.92	8.31
Cash and Cash Equivalents at End of the Period	1.61	4.02

CLICK HERE to view the financial results - <https://www.bseindia.com/xml-data/corpfiling/AttachLive/48d8fa54-0979-4a2a-b16e-6e6f496b9ecf.pdf>

Management Remarks

FINANCIAL PERFORMANCE:

- The Company recorded a strong growth in revenues in Q2FY22 as the revenues increased by 61.00% to INR 72.53 crores as against INR 49.77 crores in Q4FY21. The growth revenues is attributable to higher realisations and moderate increase in volumes.
- The EBITDA margins and profitability suffered on account of sharp increase in the prices of raw materials and freight. The Company also incurred higher employee expenses with increase in team size to support the expansion plans.
- The taxation provisioning increased during the half year ended, as the Company now falls under the normal taxation instead of MAT.

PARTICULARS	Q2 FY22	Q1 FY21
Export sales	32%	29%
Domestic sales	68%	71%

SEGMENT PERFORMANCE:

- The company recorded strong performance in speciality chemicals segment despite the challenging operating environment. The Company remains confident about passing on the increasing input costs to the customers in this segment.
- The commodity segment of the boron business continued to face a challenging environment with availability of raw materials being a roadblock. However the company continues to witness traction on the specialty part of the boron business.
- This was a challenging quarter for the bulk chemicals as the higher input costs resulted in lower margins and profitability of the segment.

PARTICULARS	Q2 FY22
Sale of specialty chemicals including exports	~64%
Sale of bulk chemicals	~36%

OPERATING ENVIRONMENT:

- The raw material prices continue to be on an upswing. However, the price increase will be passed on to the consumer with a lag of a quarter in the speciality chemicals segment.
- The freight and logistics cost continue to escalate. This will also be passed on to the consumer, however, with a lag of a quarter.
- The outlook for the speciality chemicals remains strong as the Company is witnessing strong demand from domestic as well as export customers.

Update on Capex

Debottlenecking at Roha	Multipurpose plants at Dahej	Bulk chemicals at Dahej	Specialty chemicals at Dahej	Intermediates Plant at Dahej
The company will invest ~ INR 10 crores on this project.	The company invested INR 10 crores in 2 multipurpose plants at the Dahej facility.	The company will be investing INR 50 crores in adding incremental capacity in bulk chemicals segment.	The company will invest INR 20 Crores in a dedicated plant at Dahej facility.	The company will invest INR 20 crores for expansion to manufacture intermediates for pharmaceutical and agrochemical industry.
Complete	Complete	Excessive rains in Dahej resulted in delay. However, the Company is in process on commissioning this plant	The company will use this facility for contract manufacturing. The products to be manufactured and other details remain confidential as the company has signed an NDA.	This project is expected to complete by Q4FY22
The capacity utilisations will further ramp up in Q3FY22	The capacity utilisations will further ramp up in Q3FY22	The plant is expected to begin commercial production shortly and will start contributing to the financials Q3FY22 onwards	The plant is expected to begin commercial production by Q4FY22	The company had earlier decided to invest this amount in Sulfones. However with a downturn in the international markets for the product category, the plan has been put on hold

Get in Touch

MR. OMKAR MHAMUNKAR

*Company Secretary and Compliance
Officer*

The Dharamsi Morarji Chemical Co.
Limited

omhamunkar@dmcc.com



MR. ABHISHEK MEHRA

Investor Relations Advisor

The Investment Lab

abhishek@theinvestmentlab.in

